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Abstract: Background: Kinesiophobia can be an obstacle to physical and motor activity in patients
with Parkinson’s disease (PD). PD affects patients’ independence in carrying out daily activities.
It also impacts a patient’s biopsychosocial well-being. The objective of this study was to analyze
the levels and scores of kinesiophobia in PD patients and compare them with healthy volunteers.
Methods: We deployed a case-control study and recruited 124 subjects (mean age 69.18 ± 9.12). PD
patients were recruited from a center of excellence for Parkinson’s disease (cases n = 62). Control
subjects were recruited from the same hospital (control n = 62). Kinesiophobia total scores and
categories were self-reported using the Spanish version of the Tampa Scale of Kinesiophobia (TSK-11).
Results: Differences between cases and control groups were analyzed using the Mann–Whitney U
test. Statistically significant differences (p < 0.05) were shown between groups when comparing
kinesiophobia categories (or levels) and total scores, revealing higher kinesiophobia symptoms and
levels in PD patients. All of the PD patients reported some degree of kinesiophobia (TSK-11 ≥ 18),
while the majority of PD patients (77.3%) had kinesiophobia scores rated as moderate to severe
(TSK-11 ≥ 25). On the other hand, ~45.1% of controls reported no or slight kinesiophobia and
53.2% reported moderate kinesiophobia. Conclusions: Total kinesiophobia scores were significantly
higher in PD patients compared with healthy controls, with moderate to severe kinesiophobia levels
prevailing in PD patients. Therefore, individuals living with PD should be evaluated and controlled
in order to detect initial kinesiophobia symptoms.
Keywords: movement disorders; Parkinson’s disease; musculoskeletal and neural physiological phe-
nomena
1. Introduction
Kinesiophobia is a psychological factor that manifests as an excessive fear of move-
ment or physical activity. Kinesiophobia patients believe that movement can cause re-injury
and additional pain [1]. A characteristic behavior of kinesiophobia is avoiding actions
that cause fear, with motor passivity as a symptom of this problem [2,3]. In the long-term,
kinesiophobia is associated with a decrease in physical condition, avoidance of physical
activity, functional disability, and depression [4,5]. Kinesiophobia prevalence data varies
according to what population group is being assessed. For example, it is found in 62%
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of patients after the reconstruction of the anterior cruciate ligament in the knee, 66.6% of
patients with lupus erythematosus, and 75.1% of patients with fibromyalgia [6–8].
Various authors have reported a relationship between kinesiophobia and general
psychological problems as a common feature in subjects with hallux valgus deformities [9],
cardiovascular pathology [3], fibromyalgia syndrome [8], lupus erythematosus [7], knee re-
placement [10], a reconstructed anterior cruciate ligament [6], chronic fatigue syndrome [11],
as well as chronic back and musculoskeletal pain [12–14].
Likewise, we intuited that this disorder would be present in PD patients. The literature
shows that kinesiophobia is an attribute that creates limitations regarding quality of life and
total energy expenditure [15]. This debilitating fear of movement can also be considered
a factor that intensifies one’s limited activity levels. At all times, it is important to bear
in mind that moderate physical activity has a positive impact on PD and should be used
as a treatment to alleviate symptoms such as motor dysfunction, cognitive deficits, and
depression [16].
For PD patients, kinesiophobia can be an obstacle to physical and motor activity,
as well as to independence in carrying out daily activities that impact biopsychosocial
well-being. Accordingly, it is necessary to diagnose this disorder in PD patients so that
therapeutic attention can noy only focus on reducing the fear of activity but also maintain-
ing independence and avoiding a sedentary lifestyle. Since there are no studies focusing on
this psychological factor in PD patients when compared with a control group, our study’s
objective was to analyze the levels of kinesiophobia in PD patients and compare them with
volunteers without PD. We hypothesized that kinesiophobia scores between people with
PD could be matched with neurologically healthy controls.
2. Material and Methods
2.1. Design and Sample
A descriptive and observational case-control study was carried out in a center of
excellence for Parkinson’s patients in Malaga (Spain) between October and December 2020.
A sample of 124 subjects completed the study and they were divided into persons with
Parkinson’s disease (for case group, n = 62) and a matched-paired of non-PD subjects (for
the control group, n = 62). They were recruited by a consecutive sampling method using a
successive and non-aleatorized simple method. Subjects with PD were enlisted from the
center of excellence for Parkinson’s disease and control subjects were recruited from the
same hospital. Participation selection and inclusion criteria were as follows: (1) age 50 or
higher, due to the fact that this group is likely to more frequently suffer from falls than
younger PD and healthy subjects; (2) walking autonomously with or without a walking aid;
(3) persons with PD (case group) diagnosed according to specialist of neurology criteria
and persons without PD (control group), the diagnosis, and signs suggestive of the disease.
The rules for exclusion of subjects were a (1) refusal to supply informed consent and an (2)
inability to understand and carry out the study instructions.
2.2. Procedure
Baseline measurements included general questions associated to (1) demographic
variables (e.g., age, weight, height, time since PD diagnosis) and (2) characteristics about
comorbid conditions (e.g., diabetes, obesity, musculoskeletal difficulties, vascular disorders).
Next, participants completed the Spanish Tampa Scale for Kinesiophobia (TSK-11) [17].
The scale is a psychometric tool for diagnosis, prognosis, follow-up, and clinical orienta-
tion [18,19] and it is used to assess a patient’s fear of reinjury due to movement. It consists
of 11 items, each scored 1–4. Patients indicate their degree of agreement with each of
the presented statements using a Likert-type scale from 1 (totally disagree) to 4 (totally
agree). This questionnaire is also designed to assess the avoidance dimensions of activity
and harm. Yet, in this work, we only used the total score, which has a minimum value of
11 points and a maximum value of 44 points. High scores indicate greater fear of move-
ment, i.e., higher kinesiophobia. In addition, TSK-11 total scores were categorized into
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kinesiophobia levels of fear of movement, including no fear of movement (11–17 points),
slight fear of movement (18–24 points), moderate fear of movement (25–31 points), severe
fear of movement (32–38 points), and maximum fear of movement (39–44 points) [9].
Adequate psychometric properties were reported for this scale, showing an internal
consistency of 0.78 with Cronbach’s α and a test–retest with ICC of 0.82. The validity and
reliability of the scale in the Spanish version was completed by Gomez-Perez et al. [20].
2.3. Ethical Considerations
The current study was approved by the Bioethics and Biosafety Committee (approval
number 1450610) at the University of Valencia (Spain, 2020). All volunteers gave written
informed consent before taking part in this investigation. Human and ethical experimen-
tation standards of the Declaration of Helsinki (World Medical Association) and other
organizations were respected at all times.
2.4. Sample Size Calculation
The sample size was calculated with specific levels of confidence, power, and groups
of equal size using the Epidat 4.2 Program (Consellería de Sanidade, Xunta de Galicia,
Spain; Organización Panamericana de la salud (OPS-OMS), Universidad CES, Colombia).
A total sample size of 122 participants (61 per group) was established with a confidence
level of 70%, a power of 0.80, an odds ratio of 2.0, and an expected exposure proportion of
66.67% in the PD group, as well as 50% in the controls. The total sample (124 participants)
consisted of 62 cases (38 men and 24 women) and 62 controls (37 men and 25 women).
2.5. Statistical Analysis
Statistical analysis was realized through the 25.0v tware (IBM Corp., Armonk, NY,
USA) with an alpha error of 0.05 for a 95% confidence interval (CI).
Regarding quantitative data, the Kolmogorov–Smirnov test was used to evaluate
normality. All data were dispensed as parametric tests (the Student’s t-test showed a
p-value lower than 0.05) and were described as the median ± standard deviation (SD) and
range (minimum–maximum). This contrasted between groups, as it was compared by bot
the Student’s t-test and the Mann–Whitney U tests using independent samples.
Concerning categorical data, frequencies and percentages were applied to distinguish




A sample of 124 subjects completed the study. They were divided into persons with
PD (for case group, n = 62) and matched-paired participants without PD (for the control
group, n = 62). Ages ranged between 50–84 years old. Cases and controls were matched for
age, sex, and BMI. Statistically significant differences were not shown (p > 0.05) between
groups for the descriptive data (Table 1).
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25 (40.3) 0.854 ‡
Abbreviations: BMI, body mass index; N/A, not applicable; SD, standard deviation. In all analyses, p < 0.05
(with a 95% confidence interval) was considered statistically significant. Median ± interquartile range, range
(min–max) and † Student’s t-test for independent samples were applied. ‡ Chi-squared test were used.
3.2. Outcome Measurements
Table 1 shows that, generally speaking, 100% (n = 124) of participants reported the
expected characteristics. Furthermore, 54.8% of the patients presented predisposing factors,
including 21.8% (n = 27) vascular disease, 21.8% (n = 27) osteoarticular pathology, 9.7%
(n = 12) diabetes, and 4% (n = 5) obesity.
Table 2 shows that, all of the PD patients reported some degree of kinesiophobia
(TSK-11 ≥ 18), and the majority of PD patients (77.3%) had kinesiophobia scores rated as
moderate to severe (TSK-11 ≥ 25). On the other hand, ~45.1% of controls reported no or
slight kinesiophobia and 53.2% reported moderate kinesiophobia.
Table 2. Comparisons of TSK-11 scores and categories between patients with Parkinson’s disease (PD) patients and patients
without PD (matched-paired control)s.













No 9 (7.3%) 0 (0%) 9 (14.5%)
<0.001 *
Slight 33 (26.6%) 14 (22.6%) 19 (30.6 %)
Moderate 60 (48.4%) 27 (43.5%) 33 (53.2%)
Severe 19 (15.3%) 18 (29 %) 1 (1.6 %)
Maximum 3 (2.4%) 3 (4.8%) 0 (0 %)
TSK scores 26.56 ± 5.96 (11–41) 29.21 ± 5.49 (18–41) 23.90 ± 5.21 (11–35) <0.001 †
* TSK-11, Tampa Scale Kinesiophobia. Frequency, percentage (%) and Chi-squared test (χ2) were utilized. TSK-11 category were divided
as follows: (1) 11 to 17 points: no fear of movement, (2) 18 to 24 points: slight fear of movement, (3) 25 to 31 points: moderate fear of
movement, (4) 32 to 38 points: severe fear of movement, (5) 39 to 44 points: máximum fear of movement. †, TSK-11 scores, Median ±
interquartile range, range (min–max) and Mann–Whitney U test were used. In all the analyses, p < 0.05 (with a 95% confidence interval)
was considered statistically significant (bold).
4. Discussion
In our study, the objective was to analyze the levels of kinesiophobia in PD patients
and compare them to volunteers without PD. Our hypothesis was that kinesiophobia scores
between people with PD would align with neurologically healthy controls.
Hence, this study compared kinesiophobia scores obtained from 62 subjects with PD
and 62 without PD (considered healthy control participants). The results found that the
majority of the subjects with PD suffered from kinesiophobia on one of its four levels (slight,
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moderate, severe, or maximum). The data indicate that 43.5% suffered from a “moderate”
level of fear of movement. Of PD patients, 77.3% presented high levels of kinesiophobia
(Spanish version TSK-11 scores > 25).
With the obtained data, we could suggest that these results support our hypothesis
that kinesiophobia scores between people with PD could be matched with neurologically
healthy controls.
As a novelty, it should be noted that our study provides a comparison with a control
group of non-Parkinson subjects, of whom 45.1% reported mild or no kinesiophobia and
53.2% reported moderate kinesiophobia.
In a study that carried out this research in patients with lupus erythematosus, 66.6%
of patients presented high levels of kinesiophobia. This highlighted the condition’s rela-
tionship with high levels of depression [7]. In various other studies, similar results were
obtained. In patients with fibromyalgia, 75.1% reported “maximum” kinesiophobia [8].
Moreover, 55.8% of patients undergoing knee replacement surgery presented high values
of kinesiophobia [10]. Further, patients with a high degree of hallux valgus (HV) deformity
showed increased levels of kinesiophobia. Statistically significant differences (p < 0.001)
were shown for comparison of total kinesiophobia scores among varying degrees of HV
deformity [9].
Therefore, this alteration of values in participants of our study was significantly
higher in PD patients compared to the 194 healthy control participants (29.21 ± 5.49 vs.
23.90 ± 5.21). Similar to these results were the findings of Koçyïgït and Akaltun, who
studied patients with fibromyalgia syndrome. Although fibromialgia patients share differ-
ent pathophysiological mechanisms with PD patients, significantly higher kinesiophobila
levels were found in fibromialgia patients and not in the healthy control group [8].
On the other hand, we found only one previous study of this disorder in PD patients,
which was carried out by Sütçü et al., who evaluated this phenomenon in a group of 20 PD
patients in association with fatigue and its relationship with quality of life, physical activity,
and functional capacity. They reported that fatigue and high levels of kinesiophobia
can negatively affect the independent performance of daily activities in PD patients [15].
However, their scores (39.85 ± 7.44) were evaluated with the Turkish version TSK-17
(whose values range from 17–68) as opposed to the shorter Spanish (TSK-11) used in our
study (whose values range between 11 and 44). This prevents us from comparing our
scores and theirs.
An important point to keep in mind is that the presence of this disease always has
a negative influence on patients. A review of kinesiophobia measured using TSK in
patients with neck pain highlighted that higher TSK scores predicted a longer duration of
symptoms [21]. Similarly, Luque-Suarez et al., in a systematic review of kinesiophobia in
patients with chronic musculoskeletal pain, showed that a higher degree of this problem
was associated with higher levels of pain intensity and lower quality of life [22].
Likewise, in our PD patients, we observed that motor impairment caused alterations
in gait and consequent risk of falls, leading to kinesiophobia that results from fear of
falling [23]. PD therapists and researchers set a goal of avoiding and controlling gait
disturbances to manage the risk of falls [24]. It is necessary to initially detect symptoms
of kinesiophobia in PD patients to prevent them from physical inactivity [25,26] and to
contribute to preventing them from falling [27]. Therefore, detection and monitoring of
this disorder in PD patients should be used as a tool in the prevention of falls. In fact,
there is now a new version of the Tampa Scale of Kinesiophobia that has been developed
specifically for PD [28].
More studies are needed to analyze whether gait and balance alterations in PD patients
favor the onset of kinesiophobia. Further research could determine whether the severity
of these symptoms predicts kinesiophobia. It could also investigate the interventions that
could improve said phobia.
Finally, we believe our study is important because it is the first to evaluate and classify
kinesiophobia in PD patients while also including a control group. The research, however,
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does have some limitations. First, the sample size was small and thus it would have
been beneficial to have included more participants to strengthen the results of the study,
as well as to exclude participants who presented predisposing factors. Second, despite
using a sample size calculation, it would have been useful to have carried out a prior pilot
study to obtain better quality research. The breadth of the selection criteria is another
limitation, as it favors the heterogeneity of the sample. To avoid this in future research,
larger sample sizes and longitudinal evaluation of outcomes would help determine more
definitive conclusions.
5. Conclusions
PD was found to have a negative impact on people’s kinesiophobia scores. Total
kinesiophobia scores were significantly higher in PD patients compared with healthy
controls. Moderate to severe kinesiophobia levels prevailed in PD patients. Therefore, PD
individuals should be evaluated and controlled to detect initial kinesiophobia symptoms.
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